Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is a lethal brain tumour in adults and children. However, DNA copy number and gene expression signatures indicate differences between adult and paediatric cases. To explore the genetic events underlying this distinction, we sequenced the exomes of 48 paediatric GBM samples. Somatic mutations in the H3.3-ATRX-DAXX chromatin remodelling pathway were identified in 44% of tumours (21/48). Recurrent mutations in H3F3A, which encodes the replication-independent histone 3 variant H3.3, were observed in 31% of tumours, and led to amino acid substitutions at two critical positions within the histone tail (K27M, G34R/G34V) involved in key regulatory post-translational modifications. Mutations in ATRX (α-thalassaemia/mental retardation syndrome X-linked) and DAXX (death-domain associated protein), encoding two subunits of a chromatin remodelling complex required for H3.3 incorporation at pericentric heterochromatin and telomeres, were identified in 31% of samples overall, and in 100% of tumours harbouring a G34R or G34V H3.3 mutation. Somatic TP53 mutations were identified in 54% of all cases, and in 86% of samples with H3F3A and/or ATRX mutations. Screening of a large cohort of gliomas of various grades and histologies (n = 784) showed H3F3A mutations to be specific to GBM and highly prevalent in children and young adults. Furthermore, the presence of H3F3A/ATRX-DAXX/TP53 mutations was strongly associated with alternative lengthening of telomeres and specific gene expression profiles. This is, to our knowledge, the first report to highlight recurrent mutations in a regulatory histone in humans, and our data suggest that defects of the chromatin architecture underlie paediatric and young adult GBM pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone H3 lysine27-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas.”
From Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling (2014) · cites this paper as [3]
In the citing paper
“Indeed, the K27M mutation has been observed to occur in genes encoding all forms of histone H3 (H3.1, H3.2, and H3.3) in human glioma (1,10,24).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [1]
In the citing paper
“ALT is associated with mutations in the chromatin remodeller α-thalassaemia/mental retardation syndrome X-linked (AT R X ) both in vitro and in several human cancers, including glioblastomas162–165.”
From Telomeres in cancer: tumour suppression and genome instability (2017) · cites this paper as [163]
In the citing paper
“The H3.3G34R/V mutated tumours are found almost exclusively in the cerebral hemispheres 101,102 , whereas H3.1K27M tumours are restricted to an area of the brainstem called the pons and H3.3K27M tumours can also be found along the midline of the brain 106 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [106]
In the citing paper
“A heterozygous point mutation of histone H3 occurs in more than 80% of these tumors, and results in a lysine-to-methionine substitution (H3K27M)2,3.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [2]
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Cited by
Items 401–500 of 1,001
Karsy, M. J., Gelbman, M., Shah, P., Balumbu, O., MOY, F. H., & Arslan, E. (2012) · Folia Neuropathologica · doi:10.5114/fn.2012.32361 · Cited by 116
Parental nucleosome segregation and the inheritance of cellular identity
Escobar, T. M., Loyola, A., & Reinberg, D. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00312-w · Cited by 115
Diagnostic, prognostic and predictive relevance of molecular markers in gliomas
Brandner, S., & von Deimling, A. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12246 · Cited by 120
Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression
Jain, S. U., Khazaei, S., Marchione, D. M., Lundgren, S. M., Wang, X., Weinberg, D. N., Deshmukh, S., Juretic, N., Lü, C., Allis, C. D., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006076117 · Cited by 110
“3 and are found in 92% of giant cell tumors of the bone (GCTB; G34W/L), 17% of high-grade astrocytomas (HGA; G34R/V) and 5% of osteosarcomas (G34R/W) (1, 3, 5).”
BackgroundSelf-citationEndogenous mammalian histone H3.3 exhibits chromatin-related functions during development
Bush, K. M., Yuen, B. T. K., Barrilleaux, B. L., Riggs, J. W., O’Geen, H., Cotterman, R. F., & Knoepfler, P. S. (2013) · Epigenetics & Chromatin · doi:10.1186/1756-8935-6-7 · Cited by 112
“More recently, specific coding mutations in H3f3a have been discovered by next generation sequencing in human glioblastoma tumors [31-36].”
BackgroundLoss of ATRX Suppresses Resolution of Telomere Cohesion to Control Recombination in ALT Cancer Cells
Ramamoorthy, M., & Smith, S. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.003 · Cited by 100
“3 (Schwartzentruber et al., 2012).”
The integrated genomic and epigenomic landscape of brainstem glioma
Chen, L. H., Pan, C., Diplas, B. H., Xu, C., Hansen, L. J., Wu, Y., Chen, X., Geng, Y., Sun, T., Sun, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16682-y · Cited by 111
An epigenetic gateway to brain tumor cell identity
Mack, S. C., Hubert, C. G., Miller, T. E., Taylor, M. D., & Rich, J. N. (2015) · Nature Neuroscience · doi:10.1038/nn.4190 · Cited by 109
H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers
Dong, F., Gan, H., Cheng, L., Lee, J., Zhou, H., Sarkaria, J. N., Daniels, D. J., & Zhang, Z. (2018) · eLife · doi:10.7554/elife.36696 · Cited by 113
Oncohistones: drivers of pediatric cancers
Mohammad, F., & Helin, K. (2017) · Genes & Development · doi:10.1101/gad.309013.117 · Cited by 101
“Gly34Arg/ Val (G34R/V) in pediatric high-grade gliomas (pHGGs) (Khuong-Quang et al. 2012; Schwartzentruber et al. 2012; Wu et al. 2012; Fontebasso et al. 2014; Taylor et al. 2014).”
BackgroundResultInfluentialDreveny, I., Deeves, S. E., Fulton, J., Yue, B., Messmer, M., Bhattacharya, A., Collins, H. M., & Heery, D. M. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt931 · Cited by 118
“3 variant histones have been discovered as key drivers in glioblastomas, although how this impacts on chromatin modification/remodelling remains to be determined (37,38).”
BackgroundThe Histone Variant H3.3 in Transcriptional Regulation and Human Disease
Shi, L., Wen, H., & Shi, X. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.11.019 · Cited by 119
“3 G34R or G34V mutation in one study, exhibited mutations in ATRX and DAXX as well as alternative lengthening of telomeres [99].”
BackgroundSignaling pathways in brain tumors and therapeutic interventions
Li, S., Wang, C., Chen, J., Lan, Y., Zhang, W., Kang, Z., Zheng, Y., Zhang, R., Yu, J., & Li, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01260-z · Cited by 110
Cancer genome-sequencing study design
Mwenifumbo, J. C., & Marra, M. A. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3445 · Cited by 120
Histone H3 mutations—a special role for H3.3 in tumorigenesis?
Kallappagoudar, S., Yadav, R. K., Lowe, B. R., & Partridge, J. F. (2015) · Chromosoma · doi:10.1007/s00412-015-0510-4 · Cited by 116
“2012; Schwartzentruber et al. 2012), mainly in tumors of the midline such as the thalamus, basal ganglia, and spinal cord (Sturm et al. 2012).”
BackgroundInfluentialGessi, M., Gielen, G. H., Dreschmann, V., Waha, A., & Pietsch, T. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1463-7 · Cited by 108
A Mutation in Histone H2B Represents a New Class of Oncogenic Driver
Bennett, R. L., Bele, A., Small, E. C., Will, C., Nabet, B., Oyer, J. A., Huang, X., Ghosh, R. P., Grzybowski, A. T., Yu, T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0393 · Cited by 107
“Missense mutations of H3 at amino acid position 34 and 36 are associated with gliomas, sarcomas and head and neck cancers, and lead to inhibition of methyl transferases that create H3K36 methyl marks, which are associated with open and transcribed chromatin (12-15).”
BackgroundMutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas
Fortin, J., Tian, R., Zarrabi, I., Hill, G., Williams, E., Sánchez‐Duffhues, G., Thorikay, M., Ramachandran, P., Siddaway, R., Wong, J. F., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.02.002 · Cited by 108
Machine learning classifies cancer
Wong, D., & Yip, S. S. F. (2018) · Nature · doi:10.1038/d41586-018-02881-7 · Cited by 102
Oncohistone mutations enhance chromatin remodeling and alter cell fates
Bagert, J. D., Mitchener, M. M., Patriotis, A. L., Dul, B. E., Wojcik, F., Nacev, B. A., Feng, L., Allis, C. D., & Muir, T. W. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00738-1 · Cited by 104
Pal, S., Kozono, D., Yang, X., Fendler, W., Fitts, W., Ni, J., Alberta, J. A., Zhao, J., Liu, K. X., Bian, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3691 · Cited by 101
“Driver mutations in histone genes and histone chaperones are common in pHGG and DIPG, several of these mutations are associated with poor outcomes, and targeting chromatin regulation through HDAC inhibition shows potent tumor growth suppression in vitro and in vivo (4-9).”
InfluentialCross talk of tyrosine kinases with the DNA damage signaling pathways
Mahajan, K. N., & Mahajan, N. P. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1166 · Cited by 118
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma
Kikuchi, J., Koyama, D., Wada, T., Izumi, T., Hofgaard, P. O., Bogen, B., & Furukawa, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80325 · Cited by 97
RPA Interacts with HIRA and Regulates H3.3 Deposition at Gene Regulatory Elements in Mammalian Cells
Zhang, H., Gan, H., Wang, Z., Lee, J.-H., Zhou, H., Ordog, T., Wold, M. S., Ljungman, M., & Zhang, Z. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.11.030 · Cited by 97
“3 in bone tumors (Behjati et al., 2013; Schwartzentruber et al., 2012; Wu et al., 2012).”
Understanding genomic alterations in cancer genomes using an integrative network approach
Wang, E. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.11.050 · Cited by 102
“The development of effective computational methods first requires understanding what subjects biology addresses.”
MethodSchroeder, K., Hoeman, C. M., & Becher, O. J. (2013) · Pediatric Research · doi:10.1038/pr.2013.194 · Cited by 100
Subventricular spread of diffuse intrinsic pontine glioma
Caretti, V., Bugiani, M., Freret, M. E., Schellen, P., Jansen, M. H. A., van Vuurden, D. G., Kaspers, G. J. L., Fisher, P. G., Hulleman, E., Wesseling, P., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1307-x · Cited by 101
“3 [2, 3].”
The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype
Amorim, J. P., Santos, G. S., Vinagre, J., & Soares, P. (2016) · Genes · doi:10.3390/genes7090066 · Cited by 113
“Glioblastoma (grade 4; pediatric) 44 [9] Significantly increased prevalence in pediatric GBM, compared with adult [9] Associated with the presence of mutant H3F3A/ATRX [16] 38 [16] Oligodendroglioma 20 [9] Medulloblastoma, anaplastic 18 [9] Medulloblastoma, non anaplastic 3 [9] Other embryonal tumors 10 [9] Meningioma…”
BackgroundMutations in chromatin machinery and pediatric high-grade glioma
Lulla, R. R., Saratsis, A. M., & Hashizume, R. (2016) · Science Advances · doi:10.1126/sciadv.1501354 · Cited by 106
Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
Wirth, T. C., & Kühnel, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01848 · Cited by 98
“These mutations could be interesting targets for immunotherapy as well as recently described amino acid exchange in the histone H3 gene (K27M) that is frequent in glioma (98, 99).”
BackgroundContributions of Histone Variants in Nucleosome Structure and Function
Kurumizaka, H., Kujirai, T., & Takizawa, Y. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.10.012 · Cited by 108
Bryant, L. M., Li, D., Cox, S. G., Marchione, D. M., Joiner, E. F., Wilson, K., Janssen, K. A., Lee, P., March, M., Nair, D., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc9207 · Cited by 98
Gonzalez-Perez, A., Deu-Pons, J., & Lopez-Bigas, N. (2012) · Genome Medicine · doi:10.1186/gm390 · Cited by 99
“Original sources: breast(JHU) [40,41], breast(WTSI) [42], ovary(The Cancer Gene Atlas) [43], CLL(MICINN) [44,45], colorectal(JHU) [40,46], pediatricbrain(DKFZ) [47,48], glioblastoma(TCGA) [49], glioblastoma(JHU) [50], lung(TSP) [51], pancreatic(JHU) [52];, pancreatic(OICR) and pancreatic(QCMG) are unpublished lists of…”
Chromatin Structure in Telomere Dynamics
Galati, A., Micheli, E., & Cacchione, S. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00046 · Cited by 109
“, 2011) and pediatric glioblastoma (Schwartzentruber et al., 2012) and with the establishment of a ALT mechanism of telomere maintenance (Lovejoy et al.”
BackgroundArimura, Y., Ikura, M., Fujita, R., Noda, M., Kobayashi, W., Horikoshi, N., Sun, J., Shi, L., Kusakabe, M., Harata, M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky661 · Cited by 96
“3 Lys27 and Gly34 residues, which are located in the disordered Nterminal tail, have been reported in pediatric gliomas (7,8).”
BackgroundYoshimoto, K., Hatae, R., Sangatsuda, Y., Suzuki, S. O., Hata, N., Akagi, Y., Kuga, D., Murata, H., Yamashita, K., Togao, O., et al. (2017) · Brain Tumor Pathology · doi:10.1007/s10014-017-0287-7 · Cited by 104
“mutation and K27M mutation was found to be 13 and 19%, respectively [1].”
BackgroundResultInfluentialPersonalized medicine—a modern approach for the diagnosis and management of hypertension
Savoia, C., Volpe, M., Grassi, G., Borghi, C., Rosei, E. A., & Touyz, R. M. (2017) · Clinical Science · doi:10.1042/cs20160407 · Cited by 104
Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers
Udugama, M., Sanij, E., Voon, H. P. J., Son, J., Hii, L., Henson, J. D., Chan, F. L., Chang, F. T. M., Liu, Y., Pearson, R. B., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720391115 · Cited by 94
“3, ATRX, and DAXX are initiating events in a range of cancers including brain cancers, pancreatic neuroendocrine tumors, chondroblastomas, and osteosarcomas (9, 10).”
Ezponda, T., & Licht, J. D. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2499 · Cited by 107
“Accordingly, glioblastoma samples harboring histone mutations show a distinct gene expression and DNA methylation profile (47, 50, 53).”
BackgroundLevy, M. A., Kernohan, K. D., Jiang, Y. Y., & Bérubé, N. G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu596 · Cited by 104
Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutation
Orillac, C. M., Thomas, C., Dastagirzada, Y. M., Hidalgo, E. T., Golfinos, J. G., Zagzag, D., Wisoff, J. H., Karajannis, M. A., & Snuderl, M. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0361-0 · Cited by 96
Baumhoer, D., Amary, F. M., & Flanagan, A. M. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22699 · Cited by 98
“3 residues, mutations, and genes.(33,34) Detection of the p.”
BackgroundImpact of age and gender on glioblastoma onset, progression, and management
Colopi, A., Fuda, S., Santi, S., Onorato, A., Cesarini, V., Salvati, M., Balistreri, C. R., Dolci, S., & Guida, E. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111801 · Cited by 105
ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Jackson, E. R., Duchatel, R. J., Staudt, D. E., Persson, M. L., Mannan, A., Yadavilli, S., Parackal, S., Game, S., Chong, W. C., Jayasekara, W. S. N., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0186 · Cited by 102
Histone H3.3 G34 Mutations Alter Histone H3K36 and H3K27 Methylation In Cis
Shi, L., Shi, J., Shi, X., Li, W., & Wen, H. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.04.014 · Cited by 98
“K27 and K36 are mutated to methionine (M) in pediatric diffuse intrinsic pontine glioma (DIPG) and chondroblastoma patients respectively [1, 2], and G34 mutated to various amino acids, including arginine (R) and valine (V) in pediatric glioblastoma (GBM) and tryptophan (W) and leucine (L) in giant cell tumors of the b…”
BackgroundRoux, A., Pallud, J., Saffroy, R., Edjlali, M., Debily, M.-A., Boddaert, N., Sanson, M., Puget, S., Knafo, S., Adam, C., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa024 · Cited by 102
BAHCC1 binds H3K27me3 via a conserved BAH module to mediate gene silencing and oncogenesis
Fan, H., Lu, J., Guo, Y., Li, D., Zhang, Z., Tsai, Y., Pi, W., Ahn, J. H., Gong, W., Xiang, Y., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00729-3 · Cited by 100
Harutyunyan, A. S., Chen, H., Lu, T., Horth, C., Nikbakht, H., Krug, B., Russo, C., Bareke, E., Marchione, D. M., Coradin, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108390 · Cited by 97
“Most pediatric HGGs arising in the brain midline carry somatic mutations leading to lysine-27-to-methionine substitution (K27M) in histone 3 (H3) genes (Khuong-Quang et al., 2012; Schwartzentruber et al., 2012; Wu et al., 2012).”
Self-citationACVR1 Mutations in DIPG: Lessons Learned from FOP
Taylor, K. R., Vinci, M., Bullock, A. N., & Jones, C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1298 · Cited by 87
“Remarkably, such mutations have not been identified in any other cancer type, but are also found in approximately 50% of thalamic GBM (8, 11), an anatomic location generally restricted to children, 1Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom.”
InfluentialMalignant pheochromocytoma–paraganglioma: pathogenesis, TNM staging, and current clinical trials
Román-Gonzaléz, A., & Jiménez, C. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000330 · Cited by 100
Histone supply: Multitiered regulation ensures chromatin dynamics throughout the cell cycle
Mendiratta, S., Gatto, A., & Almouzni, G. (2018) · The Journal of Cell Biology · doi:10.1083/jcb.201807179 · Cited by 105
“3A and linked to other types of tumors such as high-grade astrocytomas (Schwartzentruber et al., 2012; Sturm et al., 2012; Wu et al., 2012a; Aihara et al., 2014) and giant cell tumors of bone (Behjati et al.”
BackgroundA PRDX1 mutant allele causes a MMACHC secondary epimutation in cblC patients
Guéant, J.-L., Chéry, C., Oussalah, A., Nadaf, J., Coelho, D., Josse, T., Flayac, J., Robert, A., Koscinski, I., Gastin, I., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02306-5 · Cited by 93
“All samples were sequenced using the HiSeq X Ten Illumina System sequencer with paired-end 150-bp read length and the mean average of 35 – 37X. Bioinformatics analysis was performed as previously described 34 .”
Self-citationMichod, D., Bartesaghi, S., Khelifi, A., Bellodi, C., Berliocchi, L., Nicotera, P., & Salomoni, P. (2012) · Neuron · doi:10.1016/j.neuron.2012.02.021 · Cited by 93
“3, DAXX, and ATRX are found mutated in the brain tumor glioma (Schwartzentruber et al., 2012; Wu et al., 2012), thus suggesting that alterations of H3.”
Wiestler, B., Claus, R., Hartlieb, S. A., Schliesser, M. G., Weiß, E. K., Hielscher, T., Platten, M., Dittmann, L. M., Meisner, C., Felsberg, J., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not043 · Cited by 95
Self-citationA novel histone H4 variant H4G regulates rDNA transcription in breast cancer
Long, M., Sun, X., Shi, W., An, Y., Leung, S. T. C., Ding, D., Cheema, M. S., Macpherson, N. A., Nelson, C. J., Ausió, J., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz547 · Cited by 97
“3 and its K27M mutation, which occurs in pediatric high-grade glioma (59,60).”
BackgroundFGFR- gene family alterations in low-grade neuroepithelial tumors
Bale, T. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00898-6 · Cited by 93
ALT Positivity in Human Cancers: Prevalence and Clinical Insights
MacKenzie, D., Watters, A. K., To, J. T., Young, M. W., Muratori, J., Wilkoff, M. H., Abraham, R. G., Plummer, M. M., & Zhang, D. (2021) · Cancers · doi:10.3390/cancers13102384 · Cited by 100
“3 K27M-mutant glioblastomas were also ATRX-null [66,89,117].”
BackgroundInfluentialJayaram, H., Hoelper, D., Jain, S. U., Cantone, N., Lundgren, S. M., Poy, F., Allis, C. D., Cummings, R., Bellon, S., & Lewis, P. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1605523113 · Cited by 92
“Approximately 80% of diffuse intrinsic pontine glioma contain a lysine 27-methionine (K27M) mutation (1, 2), and 95% of chondroblastoma samples contain a K36M mutation in genes encoding either histone H3.”
BackgroundNguyen, D. N., Heaphy, C. M., de Wilde, R. F., Orr, B. A., Odia, Y., Eberhart, C. G., Meeker, A. K., & Rodríguez, F. J. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00630.x · Cited by 95
“Other studies have confirmed the increased frequency of ATRX mutations in glioblastoma (GBM) of young adults and children (21), grade II–III astrocytomas (9), as well as mutations in DAXX and H3F3A (encoding for the histone variant H3.”
BackgroundAdvances in the molecular classification of pediatric brain tumors: a guide to the galaxy
Cacciotti, C., Fleming, A. J., & Ramaswamy, V. (2020) · The Journal of Pathology · doi:10.1002/path.5457 · Cited by 96
“These mutations result in amino acid substitutions at position K27 (K27 mutant) or G34 (G34R or G34V) and are present in about 80% of midline GBMs or DIPGs in younger children [33,39,40].”
BackgroundAlternative lengthening of telomeres: remodeling the telomere architecture
Conomos, D., Pickett, H. A., & Reddel, R. R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00027 · Cited by 106
SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation
Fahey, C. C., & Davis, I. J. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026468 · Cited by 99
Mancarella, D., & Plass, C. (2021) · Genome Medicine · doi:10.1186/s13073-021-00837-7 · Cited by 94
“3 were mainly found in pediatric tumors as for instance in high grade gliomas (HGG) of children [58, 59].”
BackgroundSelf-citationExtracellular Vesicles in Brain Tumor Progression
D’Asti, E., Chennakrishnaiah, S., Lee, T. H., & Rak, J. W. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0296-1 · Cited by 97
Danussi, C., Bose, P., Parthasarathy, P. T., Silberman, P. C., Arnam, J. S. V., Vitucci, M., Tang, O. Y., Heguy, A., Wang, Y., Chan, T. A.-T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03476-6 · Cited by 96
Cheng, Z., Cheung, P., Kuo, A. J., Yukl, E. T., Wilmot, C. M., Gozani, O., & Patel, D. J. (2014) · Genes & Development · doi:10.1101/gad.246561.114 · Cited by 95
“Of note, it has been recently shown that G34V and G34R mutants of H3 are driver mutations leading to a lethal form of brain tumor (Schwartzentruber et al. 2012), suggesting a potential link between KDM2A demethylation of H3K36me2 and tumor suppression.”
BackgroundMolecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations
Miklja, Z., Pasternak, A. L., Stallard, S., Nicolaides, T. P., Kline-Nunnally, C., Cole, B., Beroukhim, R., Bandopadhayay, P., Chi, S. N., Ramkissoon, S. H., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz022 · Cited by 97
Pagès, M., Rotem, D., Gydush, G., Reed, S. C., Rhoades, J., Ha, G., Lo, C., Fleharty, M., Duran, M., Jones, R. E., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noab299 · Cited by 96
Molecular analysis of diffuse intrinsic brainstem gliomas in adults
Reyes-Botero, G., Giry, M., Mokhtari, K., Labussière, M., Idbaïh, A., Delattre, J., Laigle–Donadey, F., & Sanson, M. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1312-2 · Cited by 95
“The K27 M mutation of H3 histone has been reported in 75 % (69/92) of pediatric DIBG, and also in pediatric and young adult supratentorial glioblastoma [7, 19, 23, 24].”
BackgroundResultThe Evolving Molecular Genetics of Low-grade Glioma
Venneti, S., & Huse, J. T. (2015) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000049 · Cited by 92
“Further classification by grade, anticipating biological behavior in the absence of treatment, yields the final classification scheme: low-grade gliomas (LGGs)—(1) grade I astrocytomas: pilocytic astrocytomas, (2) grade II diffuse astrocytomas, and (3) grade II oligodendrogliomas; high-grade gliomas—(1) grade III anap…”
BackgroundFontebasso, A. M., Liu, X., Sturm, D., & Jabado, N. (2013) · Brain Pathology · doi:10.1111/bpa.12023 · Cited by 89
“3 mutations are mainly found in HGA located within the cerebral hemispheres (34, 59, 62).”
BackgroundInfluentialSelf-citationAl-Halabi, K., Stichel, D., Sievers, P., Peterziel, H., Sommerkamp, A. C., Sturm, D., Wittmann, A., Sill, M., Jäger, N., Beck, P., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02354-8 · Cited by 92
Self-citationHaase, S., Banerjee, K., Mujeeb, A., Hartlage, C. S., Núñez, F. M., Núñez, F. J., Alghamri, M. S., Kadiyala, P., Carney, S. V., Barissi, M. N., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154229 · Cited by 93
“In recent years, genetic and epigenetic hallmarks have been associated with various 95 clinical features such as age of incidence, anatomical distribution, prognosis, and 96 histological characteristics (4, 5).”
Context-dependent actions of Polycomb repressors in cancer
Koppens, M. A. J., & van Lohuizen, M. (2015) · Oncogene · doi:10.1038/onc.2015.195 · Cited by 92
Updates in prognostic markers for gliomas
Aquilanti, E., Miller, J. J., Santagata, S., Cahill, D. P., & Brastianos, P. K. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy158 · Cited by 93
Hall, M. D., Odia, Y., Allen, J. E., Tarapore, R. S., Khatib, Z. A., Niazi, T. N., Daghistani, D., Schalop, L., Chi, A. S., Oster, W., et al. (2019) · Journal of Neurosurgery Pediatrics · doi:10.3171/2019.2.peds18480 · Cited by 91
Regional identity of human neural stem cells determines oncogenic responses to histone H3.3 mutants
Bressan, R. B., Southgate, B., Ferguson, K. M., Blin, C., Grant, V., Alfazema, N., Wills, J. C., Marqués‐Torrejón, M. Á., Morrison, G. M., Ashmore, J., et al. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.01.016 · Cited by 93
“To determine whether the region-specific fetal transcriptional signatures were relevant to pHGGs, we next compared our dataset with published primary tumor transcriptomes from three independent cohorts (Paugh et al., 2010; Schwartzentruber et al., 2012; Sturm et al., 2012).”
BackgroundResultContext-specific functions of chromatin remodellers in development and disease
Gourisankar, S. P., Krokhotin, A., Wenderski, W., & Crabtree, G. R. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00666-x · Cited by 93
“Loss of ATRX, or its partner DAXX, has been correlated with the alternative lengthening of telomeres mechanism that maintains telomeres without the use of telomerase, in paediatric glioblastomas and in pancreatic neuroendocrine tumours 160,161 .”
The Role of Histone Tails in the Nucleosome: A Computational Study
Erler, J., Zhang, R., Petridis, L., Cheng, X., Smith, J. C., & Langowski, J. (2014) · Biophysical Journal · doi:10.1016/j.bpj.2014.10.065 · Cited by 97
Valle‐García, D., Qadeer, Z. A., McHugh, D., Ghiraldini, F. G., Chowdhury, A. H., Hasson, D., Dyer, M. A., Targa, F. R., & Bernstein, E. (2016) · Epigenetics · doi:10.1080/15592294.2016.1169351 · Cited by 97
Chaurasia, A., Park, S., Seo, J., & Park, C. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.8.1208 · Cited by 90
Children's Oncology Group's 2013 blueprint for research: Central nervous system tumors
Gajjar, A. J., Packer, R. J., Foreman, N. K., Cohen, K. J., Haas-Kogan, D. A., & Merchant, T. E. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24427 · Cited by 94
“These tumors are mostly glioblastomas and are present in children and young adults [50].”
BackgroundHu, Y., Shi, G. W., Zhang, L., Li, F., Jiang, Y., Jiang, S., Ma, W., Zhao, Y. B., Songyang, Z., & Huang, J. (2016) · Scientific Reports · doi:10.1038/srep32280 · Cited by 92
“Although single and double deletion of ATRX and DAXX could not initiate the ALT mechanism, histone management dysfunction and chromatin structure disorder might provide a suitable genomic environment for ALT induction 20,31,32,36,37 .”
Morel, D., Almouzni, G., Soria, J., & Postel-Vinay, S. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw552 · Cited by 89
Molecular basis for the role of oncogenic histone mutations in modulating H3K36 methylation
Zhang, Y., Shan, C., Wang, J., Bao, K., Tong, L., & Jia, S. (2017) · Scientific Reports · doi:10.1038/srep43906 · Cited by 91
Mukherjee, J., Johannessen, T.-C. A., Ohba, S., Chow, T. T., Jones, L. E., Pandita, A., & Pieper, R. O. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2269 · Cited by 93
“org Cancer Res; 78(11) June 1, 2018 2971”
BackgroundInfluentialMolecular Pathways in Gliomagenesis and Their Relevance to Neuropathologic Diagnosis
Appin, C., & Brat, D. J. (2014) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000048 · Cited by 93
Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science
Hochberg, F. H., Atai, N. A., Gonda, D. D., Hughes, M. S., Mawejje, B., Balaj, L., & Carter, R. S. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.905202 · Cited by 95
ASH1-catalyzed H3K36 methylation drives gene repression and marks H3K27me2/3-competent chromatin
Bicocca, V. T., Ormsby, T., Adhvaryu, K. K., Honda, S., & Selker, E. U. (2018) · eLife · doi:10.7554/elife.41497 · Cited by 93
“3G34R/V) (Fang et al., 2016; Lu et al., 2016; Schwartzentruber et al., 2012).”
George, S. L., Izquierdo, E., Campbell, J., Koutroumanidou, E., Proszek, P., Jamal, S., Hughes, D., Yuan, L., Marshall, L. V., Carceller, F., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.027 · Cited by 90
“For example, recurrent H3 mutations are a hallmark of paediatric high-grade glioma [14,15], and rearrangements upstream to the TERT promoter are frequent in neuroblastoma [16].”
BackgroundLa classification de l’OMS 2021 des tumeurs du système nerveux central
Figarella‐Branger, D., Appay, R., Métais, A., Tauziède‐Espariat, A., Colin, C., Rousseau, A., & Varlet, P. (2021) · Annales de Pathologie · doi:10.1016/j.annpat.2021.11.005 · Cited by 97
Reconstructing the molecular life history of gliomas
Barthel, F. P., Wesseling, P., & Verhaak, R. G. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1842-y · Cited by 91
“These observations suggest that, in IDH-wildtype astrocytoma, CDKN2A/B may be primarily important for senescence regulation Pediatric H3-mutant/IDH-wildtype diffuse gliomas are TP53 mutant in about 50% of cases, which may act as a senescence bypass event in these tumors [191].”
BackgroundInfluentialThe SWI/SNF genetic blockade: effects in cell differentiation, cancer and developmental diseases
Romero, O. A., & Sánchez‐Céspedes, M. (2013) · Oncogene · doi:10.1038/onc.2013.227 · Cited by 98
Alternative Lengthening of Telomeres: Building Bridges To Connect Chromosome Ends
Hoang, S. M., & O’Sullivan, R. J. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.009 · Cited by 90
Leach, J. L., Roebker, J. A., Schafer, A. D., Baugh, J., Chaney, B., Fuller, C. E., Fouladi, M., Lane, A., Doughman, R., Drissi, R., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa140 · Cited by 85
The dark side of histones: genomic organization and role of oncohistones in cancer
Amatori, S., Tavolaro, S., Gambardella, S., & Fanelli, M. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01057-x · Cited by 89
“Starting from 2012, somatic mutations have been discovered to be highly frequent in several histone-coding genes [76, 77].”
BackgroundATRX Loss in Glioma Results in Epigenetic Dysregulation of Cell Cycle Phase Transition
Qin, T., Mullan, B. P., Ravindran, R., Messinger, D., Siada, R. G., Cummings, J. R., Harris, M. K., Muruganand, A., Pyaram, K., Miklja, Z., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110216 · Cited by 92
Epigenomics of cancer – emerging new concepts
Hassler, M. R., & Egger, G. (2012) · Biochimie · doi:10.1016/j.biochi.2012.05.007 · Cited by 95
Bower, K., Napier, C. E., Cole, S. L., Dagg, R. A., Lau, L. M. S., Duncan, E. L., Moy, E. L., & Reddel, R. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050062 · Cited by 81
“3 may also be associated with ALT in pediatric glioblastomas [17,45], which suggests that ATRX, DAXX, and H3.”
BackgroundAdult Brainstem Gliomas With H3K27M Mutation: Radiology, Pathology, and Prognosis
Daoud, E. V., Rajaram, V., Cai, C., Oberle, R., Martin, G. R., Raisanen, J. M., White, C. L., Foong, C., Mickey, B., Pan, E., et al. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly006 · Cited by 89
Metadata
- Authors
- Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., Hovestadt, V., Albrecht, S., Kool, M., Nantel, A., Konermann, C., Lindroth, A., Jäger, N., Rausch, T., Ryzhova, M., Korbel, J. O., Hielscher, T., Hauser, P., Garami, M., Klekner, A., Bognar, L., Ebinger, M., Schuhmann, M. U., Scheurlen, W., Pekrun, A., Frühwald, M. C., Roggendorf, W., Kramm, C., Dürken, M., Atkinson, J., Lepage, P., Montpetit, A., Zakrzewska, M., Zakrzewski, K., Liberski, P. P., Dong, Z., Siegel, P., Kulozik, A. E., Zapatka, M., Guha, A., Malkin, D., Felsberg, J., Reifenberger, G., von Deimling, A., Ichimura, K., Collins, V. P., Witt, H., Milde, T., Witt, O., Zhang, C., Castelo-Branco, P., Lichter, P., Faury, D., Tabori, U., Plass, C., Majewski, J., Pfister, S. M., & Jabado, N.
- Affiliations
- McGill University and Génome Québec Innovation Centre (CA)
- German Cancer Research Center (DE)
- McGill University (CA)
- Montreal Children's Hospital (CA)
- European Molecular Biology Laboratory (DE)
- Burdenko Neurosurgery Institute (RU)
- University Children's Hospital Tübingen (DE)
- Universitätsklinikum Tübingen (DE)
- Cnopf´sche Kinderklinik (DE)
- Prof. Hess Kinderklinik (DE)
- University Hospital Augsburg (DE)
- University of Würzburg (DE)
- University Hospital in Halle (DE)
- Medical University of Lodz (PL)
- University Hospital Heidelberg (DE)
- University of Toronto (CA)
- Heinrich Heine University Düsseldorf (DE)
- University of Cambridge (GB)
- McGill University Health Centre (CA)
- Corresponding author
- Majewski, Jacek
- Pfister, Stefan M.
- Jabado, Nada
- ORCID
- Schwartzentruber, Jeremy
- Korshunov, Andrey
- Jones, David T. W.
- Pfaff, Elke
- Sturm, Dominik
- Hovestadt, Volker
- Albrecht, Steffen
- Kool, Marcel
- Lindroth, Anders
- Jäger, Natalie
- Rausch, Tobias
- Ryzhova, Marina
- Korbel, Jan O.
- Hielscher, Thomas
- Ebinger, Martin
- Schuhmann, Martin U.
- Frühwald, Michael C.
- Dürken, Matthias
- Atkinson, Jeffrey
- Lepage, Pierre
- Zakrzewska, Magdalena
- Liberski, Pawel P.
- Siegel, Peter
- Kulozik, Andreas E.
- Zapatka, Marc
- Guha, Abhijit
- Malkin, David
- Felsberg, Jörg
- Reifenberger, Guido
- Ichimura, Koichi
- Collins, V. Peter
- Witt, Hendrik
- Milde, Till
- Witt, Olaf
- Zhang, Cindy
- Lichter, Peter
- Faury, Damien
- Tabori, Uri
- Plass, Christoph
- Majewski, Jacek
- Pfister, Stefan M.
- Jabado, Nada
- Venue
- Nature
- Published
- 2012-01-29
- Volume
- 482
- Issue
- 7384
- Pages
- 226-231
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2158233796
- Cited by
- 2,631
- References
- 35
- Citations by year
- 2026: 109 · 2025: 138 · 2024: 188 · 2023: 189 · 2022: 200 · 2021: 226 · 2020: 238 · 2019: 188 · 2018: 166 · 2017: 200 · 2016: 174 · 2015: 165 · 2014: 189 · 2013: 166 · 2012: 90
- FWCI
- 92.99
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-03-28)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- NPARC (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Funders
- Cancer Research Institute
- Genome Canada
- Brain Tumour Charity (10/106)
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- H3F3A mutation, histone H3.3, ATRX mutation, chromatin remodeling, somatic mutations, TP53 mutation, H3K27M mutation, histone modifications, histone deacetylase inhibitors
- MeSH terms
- X-linked Nuclear Protein, Base Sequence, Child, Chromatin, DNA Mutational Analysis, DNA Helicases, Glioblastoma, Histones, Humans, Molecular Sequence Data, Mutation, Nuclear Proteins, Tumor Suppressor Protein p53, Telomere, Molecular Chaperones, Gene Expression Profiling, Chromatin Assembly and Disassembly, Adaptor Proteins, Signal Transducing, Co-Repressor Proteins, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.